CHOP Division of Pediatric Endocrinology, Abramson Building, Office 804F, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA.
Children's Hospital of Philadelphia, The Hub for Clinical Collaboration, Division of Endocrinology, 7th floor, 3500 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Adv Pediatr. 2022 Aug;69(1):203-217. doi: 10.1016/j.yapd.2022.03.005. Epub 2022 Jun 17.
Growth hormone (GH) is an injectable medication originally used to replace the deficiency of the hormone, but has expanded to treating conditions that may reduce growth and adult height even when the body maintains endogenous GH production. In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Willi Syndrome, small for gestational age (SGA) without catch-up growth, idiopathic short stature, Turner syndrome, SHOX gene haploinsufficiency, Noonan Syndrome, and chronic renal insufficiency. We characterize the growth patterns and effects of GH treatment in each of these indications. We also review patterns of growth that warrant referral to a pediatric endocrinologist, as well as safety updates. This review is intended to guide practitioners on the initial evaluation and management of patients with short stature, and the indications for GH therapy.
生长激素(GH)是一种可注射药物,最初用于替代激素缺乏症,但已扩展到治疗可能导致生长和成人身高降低的病症,即使体内维持内源性 GH 产生也是如此。在美国,儿科 GH 治疗有 8 种经食品和药物管理局(FDA)批准的适应证:生长激素缺乏症、普拉德-威利综合征、小于胎龄儿(SGA)且未追赶生长、特发性身材矮小、特纳综合征、SHox 基因单倍体不足、努南综合征和慢性肾功能不全。我们描述了这些适应证中 GH 治疗的生长模式和效果。我们还回顾了需要转介给儿科内分泌医生的生长模式,以及安全性更新。本综述旨在指导医生对身材矮小患者进行初步评估和管理,以及 GH 治疗的适应证。